RecruitingRecruiting
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
NCT06471257 · AstraZeneca
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Double-blind, Multicentre, Event-driven, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Symptomatic Chinese Adults With Asthma (BAIYUN)
About this study
This is a randomized, double-blind, multicenter, event-driven, parallel group, Phase III study to assess the efficacy and safety of budesonide and albuterol metered dose inhaler (MDI) versus albuterol sulfate (AS) MDI in symptomatic Chinese adults with asthma. Both treatments will be administered as needed in response to asthma symptoms or prior to exercise. Approximately 1000 participants who meet the eligibility criteria will be randomized.
The study will consist of 3 periods:
1. Screening period: 14 to 28 days
2. Treatment period: minimum of 24 weeks and maximum of 52 weeks
3. Safety follow-up period: occur 2 weeks (± 4 days) after Visit 8, EOS or PDV, whichever occurs first
1000 participants who meet the eligibility criteria will be randomly assigned in a 1:1 ratio to receive one of the following 2 treatments to be used as reliever therapy on top of usual maintenance treatment:
* BDA MDI 160/180 μg (administered as 2 actuations of BDA MDI 80/90 µg) as needed
* AS MDI 180 μg (administered as 2 actuations of AS MDI 90 μg) as needed
Eligibility criteria
Inclusion Criteria:
1. Documented physician-diagnosed asthma for at least 12 months prior to Visit 1
2. Receiving 1 of the scheduled asthma maintenance therapies for 3 months with stable dosing for at least the last 4 weeks before Visit 1
3. Pre-bronchodilator FEV1 of ≥ 40% to \< 90% predicted normal value for adults.
4. Documented reversibility to albuterol
5. A documented history of at least one severe asthma exacerbation within 12 months before Visit 1
6. ACQ-7 score ≥ 1.5 assessed at Visit 1
7. ACQ-5 score ≥ 1.5 assessed at Visit 2
8. Receiving inhaled SABA as needed prior to Visit 1 for at least 3 months
9. Use of Sponsor-provided salbutamol sulfate inhalation aerosol as needed medication due to asthma symptoms on at least 3 days during the last week of the run-in period before Visit 2
10. Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited
11. Able to perform acceptable and reproducible PEF measurements as assessed by the investigator
12. BMI \< 40 kg/m2
13. Negative pregnancy test (urine at Visit 1) for female participants of childbearing potential
14. Women of childbearing potential must agree to prevent pregnancy
15. Compliance: must be willing to remain at the study site as required per protocol and complete all visit assessments
Exclusion Criteria:
1. Chronic obstructive pulmonary disease or other significant lung disease
2. Oral/SCS use (any dose) within 6 weeks before Visit 1
3. Chronic use of OCS ≥ 3 weeks use in 3 months prior to Visit 1
4. Having received any marketed or investigational biologic within 3 months or 5 half-lives before Visit 1, whichever is longer, or any other prohibited medication
5. Current smokers, former smokers with \> 10 pack-years history, or former smokers who stopped smoking \< 6 months before Visit 1
6. Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s) within last 5 years of Visit 1
7. Completed treatment for lower respiratory infection or asthma exacerbation within 6 weeks of Visit 1
8. Upper respiratory infection involving antibiotic treatment not resolved within 7 days before Visit 1
9. Clinically significant laboratory abnormalities
10. Historical or current evidence of a clinically significant disease
11. Cancer not in complete remission for at least 5 years before Visit 1
12. History of psychiatric disease, intellectual deficiency, poor motivation, or other conditions if their magnitude is limiting informed consent validity
13. Have a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients
14. Inability to abstain from protocol-defined prohibited medications during the study
15. Having received a live attenuated vaccination within 7 days of Visit 1
16. Currently pregnant or breastfeeding
17. Participants who experience \> 1 asthma exacerbation during the screening period
Study design
Enrollment target: 1000 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2024-06-17
Estimated completion: 2027-10-04
Last updated: 2026-09-21
Interventions
Combination Product: Budesonide/Albuterol metered dose inhaler, MDICombination Product: Albuterol sulfate metered dose inhaler, MDI
Primary outcomes
- • Time to first severe asthma exacerbation (24 to 52 weeks)
Sponsor
AstraZeneca · industry
Contacts & investigators
ContactAstraZeneca Clinical Study Information Center · contact · information.center@astrazeneca.com · 1-877-240-9479
All locations (102)
Research SiteRecruiting
Baotou, China
Research SiteRecruiting
Baotou, China
Research SiteActive Not Recruiting
Beijing, China
Research SiteRecruiting
Beijing, China
Research SiteRecruiting
Beijing, China
Research SiteRecruiting
Beijing, China
Research SiteRecruiting
Changchun, China
Research SiteRecruiting
Changchun, China
Research SiteRecruiting
Changsha, China
Research SiteRecruiting
Changsha, China
Research SiteRecruiting
Chengdu, China
Research SiteRecruiting
Chengdu, China
Research SiteRecruiting
Chengdu, China
Research SiteRecruiting
Chengdu, China
Research SiteRecruiting
Chengdu, China
Research SiteRecruiting
Chizhou, China
Research SiteRecruiting
Chongqing, China
Research SiteRecruiting
Chongqing, China
Research SiteCompleted
Chongqing, China
Research SiteRecruiting
Dazhou, China
Research SiteRecruiting
Deyang, China
Research SiteRecruiting
Ganzhou, China
Research SiteRecruiting
Guangyuan, China
Research SiteActive Not Recruiting
Guangzhou, China
Research SiteRecruiting
Guangzhou, China
Research SiteCompleted
Guangzhou, China
Research SiteRecruiting
Guangzhou, China
Research SiteRecruiting
Guangzhou, China
Research SiteRecruiting
Guangzhou, China
Research SiteActive Not Recruiting
Haikou, China
Research SiteRecruiting
Hangzhou, China
Research SiteWithdrawn
Hangzhou, China
Research SiteRecruiting
Hefei, China
Research SiteRecruiting
Hefei, China
Research SiteRecruiting
Hefei, China
Research SiteWithdrawn
Heifei, China
Research SiteRecruiting
Hohhot, China
Research SiteRecruiting
Hohhot, China
Research SiteRecruiting
Huizhou, China
Research SiteRecruiting
Huizhou, China
Research SiteRecruiting
Jinan, China
Research SiteRecruiting
Jinhua, China
Research SiteRecruiting
Jining, China
Research SiteRecruiting
Kunming, China
Research SiteRecruiting
Lanzhou, China
Research SiteRecruiting
Linhai, China
Research SiteRecruiting
Luoyang, China
Research SiteRecruiting
Luzhou, China
Research SiteWithdrawn
Luzhou, China
Research SiteRecruiting
Mianyang, China
Research SiteRecruiting
Nanchang, China
Research SiteRecruiting
Nanchong, China
Research SiteRecruiting
Nanjing, China
Research SiteRecruiting
Nanjing, China
Research SiteWithdrawn
Nantong, China
Research SiteWithdrawn
Ningbo, China
Research SiteWithdrawn
Panjin, China
Research SiteRecruiting
Panzhihua, China
Research SiteRecruiting
Pingxiang, China
Research SiteRecruiting
Qingdao, China
Research SiteRecruiting
Rui’an, China
Research SiteWithdrawn
Sanya, China
Research SiteRecruiting
Shanghai, China
Research SiteCompleted
Shanghai, China
Research SiteRecruiting
Shanghai, China
Research SiteRecruiting
Shenyang, China
Research SiteRecruiting
Shenyang, China
Research SiteRecruiting
Shenzhen, China
Research SiteRecruiting
Shenzhen, China
Research SiteRecruiting
Shijiazhuang, China
Research SiteRecruiting
Shijiazhuang, China
Research SiteRecruiting
Suining, China
Research SiteRecruiting
Taiyuan, China
Research SiteRecruiting
Taiyuan, China
Research SiteRecruiting
Tianjin, China
Research SiteRecruiting
Ürümqi, China
Research SiteRecruiting
Wenzhou, China
Research SiteRecruiting
Wenzhou, China
Research SiteRecruiting
Wuhan, China
Research SiteActive Not Recruiting
Wuhan, China
Research SiteWithdrawn
Wuhu, China
Research SiteRecruiting
Xi'an, China
Research SiteRecruiting
Xiamen, China
Research SiteRecruiting
Xintai, China
Research SiteRecruiting
Xinxiang, China
Research SiteRecruiting
Xuzhou, China
Research SiteRecruiting
Xuzhou, China
Research SiteRecruiting
Yangzhou, China
Research SiteRecruiting
Yibin, China
Research SiteRecruiting
Yinchuan, China
Research SiteCompleted
Yinchuan, China
Research SiteWithdrawn
Yueyang, China
Research SiteRecruiting
Yuhuan, China
Research SiteRecruiting
Zhangzhou, China
Research SiteRecruiting
Zhengzhou, China
Research SiteRecruiting
Zhengzhou, China
Research SiteRecruiting
Zhuhai, China
Research SiteRecruiting
Zhuji, China
Research SiteRecruiting
Zibo, China
Research SiteWithdrawn
Zigong, China
Research SiteRecruiting
Zunyi, China
Research SiteActive Not Recruiting
Hong Kong, Hong Kong